Skip to main content

Advertisement

Table 1 Baseline characteristics per treatment group, non-imputed data

From: Similar short-term clinical response to high-dose versus low-dose methotrexate in monotherapy and combination therapy in patients with rheumatoid arthritis

  MTX monotherapy (n = 523) MTX + csDMARDs (n = 266) MTX + glucocorticoids (n = 615)
Number   Number   Number  
Age at first visit (years) 522 47.9 (13.1) 264 44.6 (10.9) 479 48.3 (14.8)
Gender (% female) 520 78 266 83 609 81
Body mass index 281 26.6 (6.7) 184 27.6 (6.3) 272 27.2 (6.0)
Symptom duration at diagnosis median (IQR) 451 365 (169–731) 266 730 (365–1095) 482 458 (181–1095)
Rheumatoid factor (% positive) 511 77 263 84 585 81
ACPA (% positive) 300 72 98 85 342 76
Erosions present (% positive) 305 40 62 55 293 52
ESR 462 56.5 (33.0) 241 69.3 (31.7) 543 59.5 (35.5)
CRP 415 33.1 (33.9) 219 40.3 (35.5) 515 37.7 (37.1)
HAQ 439 1.0 (0.6) 249 1.1 (0.6) 506 1.3 (0.7)
DAS 314 3.7 (1.2) 189 4.0 (0.96) 347 3.9 (1.2)
DAS 28 340 5.7 (1.5) 192 6.2 (1.2) 415 6.0 (1.5)
MTX dose (% high dose) 523 28 266 14 615 46
Follow-up duration (days) 523 134 (28) 266 135 (28) 615 139 (31)
  1. Data per number of patients are means (SD), unless indicated otherwise. MTX methotrexate, csDMARDs conventional synthetic disease-modifying antirheumatic drugs, IQR inter quartile range, ACPA anti-citrullinated protein antibodies, ESR erythrocyte sedimentation rate, CRP C-reactive protein, HAQ Health Assessment Questionnaire, DAS Disease Activity Score